The discovery of ligands that bind specifically to cancer cells is essential for NDDS delivery, and peptide binding to liposomes has been used to selectively deliver drugs to kill tumor cells with EGFR mutations (Song et al., 2008; Song et al., 2009). This evidence concerns the gene EGFR and cancer.